Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Shaw Christopher E) "

Sökning: WFRF:(Shaw Christopher E)

  • Resultat 41-48 av 48
  • Föregående 1234[5]
Sortera/gruppera träfflistan
  • Iacoangeli, Alfredo, et al. (författare)
  • SCFD1 expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed
  • 2021
  • Ingår i: Brain Communications. - : Oxford University Press. - 2632-1297. ; 3:4
  • Tidskriftsartikel (refereegranskat)abstract
    • Evidence indicates that common variants found in genome-wide association studies increase risk of disease through gene regulation via expression Quantitative Trait Loci. Using multiple genome-wide methods, we examined if Single Nucleotide Polymorphisms increase risk of Amyotrophic Lateral Sclerosis through expression Quantitative Trait Loci, and whether expression Quantitative Trait Loci expression is consistent across people who had Amyotrophic Lateral Sclerosis and those who did not. In combining public expression Quantitative Trait Loci data with Amyotrophic Lateral Sclerosis genome-wide association studies, we used Summary-data-based Mendelian Randomization to confirm that SCFD1 was the only gene that was genome-wide significant in mediating Amyotrophic Lateral Sderosis risk via expression Quantitative Trait Loci (Summary-data-based Mendelian Randomization beta = 0.20, standard error = 0.04, P-value = 4.29 x 10(-6)). Using post-mortem motor cortex, we tested whether expression Quantitative Trait Loci showed significant differences in expression between Amyotrophic Lateral Sclerosis (n= 76) and controls (n= 25), genome-wide. Of 20 757 genes analysed, the two most sign ificant expression Quantitative Trait Loci to show differential in expression between Amyotrophic Lateral Sclerosis and controls involve two known Amyotrophic Lateral Sclerosis genes (SCFD1 and VCP). Cis-acting SCFD1 expression Quantitative Trait Loci downstream of the gene showed significant differences in expression between Amyotrophic Lateral Sclerosis and controls (top expression Quantitative Trait Lod beta = 0.34, standard error = 0.063, P-value = 4.54 x 10(-7)). These SCFD1 expression Quantitative Trait Loci also significantly modified Amyotrophic Lateral Sclerosis survival (number of samples = 4265, hazard ratio = 1.11, 95% confidence interval = 1.05-1.17, P-value = 2.06 x 10(-4)) and act as an Amyotrophic Lateral Sclerosis trans-expression Quantitative Trait Loci hotspot for a wider network of genes enriched for SCFD1 function and Amyotrophic Lateral Sderosis pathways. Using gene-set analyses, we found the genes that correlate with this trans-expression Quantitative Trait Loci hotspot significantly increase risk of Amyotrophic La teral Sderosis (beta = 0.247, standard deviation = 0.017, P= 0.001) and schizophrenia (beta = 0.263, standard deviation = 0.008, P-value 1.18 x 10(-5)), a disease that genetically correlates with Amyotrophic Lateral Sclerosis. In summary, SCFD1 expression Quantitative Trait Lod are a major factor in Amyotrophic Lateral Sderosis, not only influencing disease risk but are differentially expressed in post-mortem Amyotrophic Lateral Sclerosis. SCFD1 expression Quantitative Trait Loci show distinct expression profiles in Amyotrophic Lateral Sclerosis that correlate with a wider network of genes that also confer risk of the disease and modify the disease's duration.
  • Li, Yan, et al. (författare)
  • Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques
  • 2022
  • Ingår i: Neurology. - : Lippincott Williams & Wilkins. - 0028-3878. ; 98:7, s. 688-699
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and Objectives To determine the diagnostic accuracy of a plasma Aβ42/Aβ40 assay in classifying amyloid PET status across global research studies using samples collected by multiple centers that utilize different blood collection and processing protocols.MethodsPlasma samples (n = 465) were obtained from 3 large Alzheimer disease (AD) research cohorts in the United States (n = 182), Australia (n = 183), and Sweden (n = 100). Plasma Aβ42/Aβ40 was measured by a high precision immunoprecipitation mass spectrometry (IPMS) assay and compared to the reference standards of amyloid PET and CSF Aβ42/Aβ40.ResultsIn the combined cohort of 465 participants, plasma Aβ42/Aβ40 had good concordance with amyloid PET status (receiver operating characteristic area under the curve [AUC] 0.84, 95% confidence interval [CI] 0.80-0.87); concordance improved with the inclusion of APOE ϵ4 carrier status (AUC 0.88, 95% CI 0.85-0.91). The AUC of plasma Aβ42/Aβ40 with CSF amyloid status was 0.85 (95% CI 0.78-0.91) and improved to 0.93 (95% CI 0.89-0.97) with APOE ϵ4 status. These findings were consistent across the 3 cohorts, despite differences in protocols. The assay performed similarly in both cognitively unimpaired and impaired individuals.DiscussionPlasma Aβ42/Aβ40 is a robust measure for detecting amyloid plaques and can be utilized to aid in the diagnosis of AD, identify those at risk for future dementia due to AD, and improve the diversity of populations enrolled in AD research and clinical trials.Classification of EvidenceThis study provides Class II evidence that plasma Aβ42/Aβ40, as measured by a high precision IPMS assay, accurately diagnoses brain amyloidosis in both cognitively unimpaired and impaired research participants.
  • Postmus, Iris, et al. (författare)
  • Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins.
  • 2014
  • Ingår i: Nature communications. - : Nature Publishing Group. - 2041-1723. ; 5
  • Tidskriftsartikel (refereegranskat)abstract
    • Statins effectively lower LDL cholesterol levels in large studies and the observed interindividual response variability may be partially explained by genetic variation. Here we perform a pharmacogenetic meta-analysis of genome-wide association studies (GWAS) in studies addressing the LDL cholesterol response to statins, including up to 18,596 statin-treated subjects. We validate the most promising signals in a further 22,318 statin recipients and identify two loci, SORT1/CELSR2/PSRC1 and SLCO1B1, not previously identified in GWAS. Moreover, we confirm the previously described associations with APOE and LPA. Our findings advance the understanding of the pharmacogenetic architecture of statin response.
  • Sproviero, William, et al. (författare)
  • ATXN2 trinucleotide repeat length correlates with risk of ALS
  • 2017
  • Ingår i: Neurobiology of Aging. - 0197-4580 .- 1558-1497. ; 51, s. 178.e1-178.e9
  • Tidskriftsartikel (refereegranskat)abstract
    • We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclerosis (ALS). Two new case-control studies, a British dataset of 1474 ALS cases and 567 controls, and a Dutch dataset of 1328 ALS cases and 691 controls were analyzed. In addition, to increase power, we systematically searched PubMed for case-control studies published after 1 August 2010 that investigated the association between ATXN2 intermediate repeats and ALS. We conducted a meta-analysis of the new and existing studies for the relative risks of ATXN2 intermediate repeat alleles of between 24 and 34 CAG trinucleotide repeats and ALS. There was an overall increased risk of ALS for those carrying intermediate sized trinucleotide repeat alleles (odds ratio 3.06 [95% confidence interval 2.37-3.94]; p = 6 × 10(-18)), with an exponential relationship between repeat length and ALS risk for alleles of 29-32 repeats (R(2) = 0.91, p = 0.0002). No relationship was seen for repeat length and age of onset or survival. In contrast to trinucleotide repeat diseases, intermediate ATXN2 trinucleotide repeat expansion in ALS does not predict age of onset but does predict disease risk.
  • Turner, Martin R, et al. (författare)
  • Cortical involvement in four cases of primary lateral sclerosis using [(11)C]-flumazenil PET.
  • 2007
  • Ingår i: Journal of Neurology. - 0340-5354 .- 1432-1459. ; 254:8, s. 1033-6
  • Tidskriftsartikel (refereegranskat)abstract
    • Four PLS patients underwent cerebral [(11)C]-flumazenil PET. They were compared firstly with a group of controls, then later directly with a group of sporadic ALS patients and a familial ALS group homozygous for the 'D90A' SOD1 gene mutation. There was a similar pattern of decreased binding in PLS patients when compared to controls as that seen in a previous study of sporadic ALS patients, supporting the concept that PLS is part of the same overall spectrum of MND. However, in direct group comparisons, both sporadic and homD90A ALS patients demonstrated relative decreases in anterior and orbito-frontal binding compared to PLS patients, suggesting that there may be differences in cortical vulnerability between phenotypic groups.
  • Turner, Martin R, et al. (författare)
  • Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis.
  • 2007
  • Ingår i: Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. - 1471-180X. ; 8:6, s. 343-7
  • Tidskriftsartikel (refereegranskat)abstract
    • Patients homozygous for the D90A mutation of the SOD1 gene (homD90A) demonstrate markedly slower progression of disease than those patients with sporadic ALS (SALS). PET studies have demonstrated a different cortical vulnerability in the two groups, reflected also in neurophysiological studies showing reduced cortical excitability in homD90A. Voxel-based morphometric analysis of magnetic resonance images (MRIs) enables the detection of regional differences in grey matter volume, and can be used to localize cortical atrophy in vivo. In this study, segmented, spatially normalized, modulated and smoothed grey matter portions of the MRIs from 23 SALS and seven homD90A patients with similar disability, were compared with those from 28 healthy control subjects. The SALS group showed bilateral areas of atrophy mainly confined to motor and pre-motor cortices. Cortical changes in the homD90A group were more pronounced within the frontal lobes when both were compared with healthy controls. This study provides further evidence for a different pattern of cortical neuronal vulnerability in homD90A versus SALS patients that may provide insight as to their slower rate of disease progression.
  • van de Giessen, Elsmarieke, et al. (författare)
  • Association study on glutathione S-transferase omega 1 and 2 and familial ALS
  • 2008
  • Ingår i: Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders. - 1466-0822 .- 1743-4483. ; 9:2, s. 81-84
  • Tidskriftsartikel (refereegranskat)abstract
    • Glutathione S-transferase omega 1 and 2 (GSTO1 and 2) protect from oxidative stress, a possible pathogenic mechanism underlying the pathogenesis of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Significant association of age of onset in Alzheimer's patients with GSTO1 and 2 had recently been identified, suggesting a possibly similar association with ALS. In this study 12 Hapmap tagged SNPs in GSTO1 and 2 were genotyped in 251 Caucasian British, Australian and Swedish familial ALS (FALS) cases. No association was found for age of onset and survival of FALS in the British and Australian patients. In the Swedish patients, association for age of onset was found with several SNPs (p = 0.003-0.048). These results suggest a possible effect of the GSTO1 and 2 locus on age of onset of FALS.
  • Vrooman, Lynda M., et al. (författare)
  • Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age
  • 2017
  • Ingår i: Biology of blood and marrow transplantation. - 1083-8791 .- 1523-6536. ; 23:8, s. 1327-1334
  • Tidskriftsartikel (refereegranskat)abstract
    • Very young children undergoing hematopoietic cell transplantation (HCT) are a unique and vulnerable population. We analyzed outcomes of 717 patients from 117 centers who survived relapse free for year after allogeneic myeloablative HCT for hematologic malignancy at <3 years of age, between 1987 and 2012. The median follow-up was 8.3 years (range, 1.0 to 26.4 years); median age at follow-up was 9 years (range, 2 to 29 years). Ten-year overall and relapse-free survival were 87% (95% confidence interval [CI], 85% to 90%) and 84% (95% CI, 81% to 87%). Ten-year cumulative incidence of relapse was 11% (95% CI, 9% to 13%). Of 84 deaths, relapse was the leading cause (43%). Chronic graft-versus-host-disease 1 year after HCT was associated with increased risk of mortality (hazard ratio [HR], 2.1; 95% CI, 1.3 to 3.3; P=.0018). Thirty percent of patients experienced >= 1 organ toxicity/late effect >1 year after HCT. The most frequent late effects included growth hormone deficiency/growth disturbance (10-year cumulative incidence, 23%; 95% CI, 19% to 28%), cataracts (18%; 95% CI, 15% to 22%), hypothyroidism (13%; 95% CI, 10% to 16%), gonadal dysfunction/infertility requiring hormone replacement (3%; 95% CI, 2% to 5%), and stroke/seizure (3%; 95% CI, 2% to 5%). Subsequent malignancy was reported in 3.6%. In multivariable analysis, total body irradiation (TBI) was predictive of increased risk of cataracts (HR, 17.2; 95% CI, 7.4 to 39.8; P <.001), growth deficiency (HR, 3.5; 95% CI, 2.2 to 5.5; P <.001), and hypothyroidism (HR, 5.3; 95% CI, 3.0 to 9.4; P <.001). In summary, those who survived relapse free year after HCT for hematologic malignancy at <3 years of age had favorable overall survival. Chronic graft-versus host-disease and TBI were associated with adverse outcomes. Future efforts should focus on reducing the risk of relapse and late effects after HCT at early age.
Skapa referenser, mejla, bekava och länka
  • Resultat 41-48 av 48
  • Föregående 1234[5]
Typ av publikation
tidskriftsartikel (47)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (47)
övrigt vetenskapligt (1)
Shaw, Christopher E. (24)
Al-Chalabi, Ammar (22)
van den Berg, Leonar ... (19)
Andersen, Peter M. (18)
Veldink, Jan H. (18)
Robberecht, Wim (16)
visa fler...
Shatunov, Aleksey (14)
Landers, John E. (14)
Hardiman, Orla (14)
Van Damme, Philip (13)
Morrison, Karen E. (13)
van Es, Michael A (13)
Shaw, Pamela J. (13)
van Rheenen, Wouter (12)
Silani, Vincenzo (12)
Meininger, Vincent (9)
Glass, Jonathan D (9)
Hofman, Albert (8)
Weber, Markus (8)
Ratti, Antonia (8)
Chio, Adriano (8)
Melki, Judith (8)
Traynor, Bryan J. (7)
Uitterlinden, Andre ... (7)
Ludolph, Albert C (7)
Savani, Bipin N (7)
Hematti, Peiman (7)
Diekstra, Frank P (7)
Lazarus, Hillard M (6)
Rivadeneira, Fernand ... (6)
McLaughlin, Russell ... (6)
Brown, Robert H (6)
Calvo, Andrea (6)
D'Alfonso, Sandra (5)
Salomaa, Veikko (5)
Olsson, Richard (5)
Seo, Sachiko (5)
de Carvalho, Mamede (5)
Powell, John (5)
Caulfield, Mark J. (5)
Munroe, Patricia B. (5)
Meitinger, Thomas (5)
Kamble, Rammurti T. (5)
Pulsipher, Michael A ... (5)
Elliott, Paul (5)
Troakes, Claire (5)
Weishaupt, Jochen H. (5)
Cereda, Cristina (5)
Kasow, Kimberly A. (5)
Comi, Giacomo P (5)
visa färre...
Umeå universitet (27)
Uppsala universitet (14)
Karolinska Institutet (11)
Lunds universitet (10)
Göteborgs universitet (6)
Högskolan Dalarna (1)
Engelska (48)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (44)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy